RussianPatents.com
 

Immunomodulator. RU patent 2497514.

IPC classes for russian patent Immunomodulator. RU patent 2497514. (RU 2497514):

A61P7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61K47/02 - Inorganic compounds
A61K39/42 - viral
A61K36/23 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)
A61K35/407 -
A61K35/28 - Marrow; Spleen
A61K35/26 - Lymph; Lymph-glands; Thymus
A61K35/16 - Plasma; Serum
A61K31/375 -
A61K31/192 -
A61K31/191 -
Another patents in same IPC classes:
Method for normalising spontaneous erythrocyte aggregation in newborn piglets suffered acute hypoxia at birth / 2494734
Invention refers to veterinary science, and may be used for normalising spontaneous erythrocyte aggregation (SEA) in newborn piglets suffered acute hypoxia at birth. That is ensured by prescribing crezacin 4 mg/kg a day of fed-on plan in the morning for five days combined with gamavit 0.03 mg/kg intramuscularly once a day in the morning for five days in the newborn piglets suffered acute hypoxia at birth.
Method of normalisation of spontaneous erythrocyte aggregation in piglets with dairy-vegetative nutrition with bronchitis / 2493835
Invention relates to veterinary, and can be applied for normalisation of spontaneous erythrocyte aggregation (SEA) in piglets with dairy-vegetative nutrition with bronchitis. For this purpose to piglets of diary-vegetative nutrition with bronchitis simultaneously prescribed are crezacine in dose 4 mg/kg per day in scheme of drinking in the morning for five days and gamavit in dose 0.03 mg/kg per day intramuscularly one time per day, for five days.
Method for normalising spontaneous erythrocyte aggregation in sows with arthritis / 2491060
Invention refers to veterinary science, and may be used for normalising spontaneous erythrocyte aggregation (SEA) in sows with arthritis. That is ensured by prescribing crezacin 4 mg/kg a day of fed-on plan in the morning for five days combined with gamavit 0.03 mg/kg intramuscularly once a day in the morning for five days.
Bicyclosubstituted pyrazolon azo derivatives, method for production and pharmaceutical use thereof Bicyclosubstituted pyrazolon azo derivatives, method for production and pharmaceutical use thereof / 2488582
Invention relates to bicyclosubstituted pyrazolon azo derivatives of formula
Method for normalising spontaneous erythrocyte aggregation in suckling piglets with arthritis / 2488387
Invention refers to veterinary science, and may be used for normalising spontaneous erythrocyte aggregation in suckling piglets with arthritis. That is ensured by prescribing crezacin 4 mg/kg a day of fed-on plan in the morning for five days combined with gamavit 0.03 mg/kg intramuscularly once a day in the morning for five days in the suckling piglets with arthritis.
Method for normalising spontaneous erythrocyte aggregation in newborn piglets with dyspepsia / 2488386
Invention refers to veterinary science, and may be used for normalising spontaneous erythrocyte aggregation in newborn piglets with dyspepsia. That is ensured by prescribing crezacin 4 mg/kg a day of fed-on plan in the morning for five days combined with gamavit 0.03 mg/kg intramuscularly once a day in the morning for five days.
Medication modulating concentration of ferritin in blood serum Medication modulating concentration of ferritin in blood serum / 2486895
Invention relates to field of pharmaceutics and medicine and deals with application of trecresan as medication, which modulates concentration of ferritin in blood serum.
Mediation increasing level of lactoferrin in organism Mediation increasing level of lactoferrin in organism / 2486894
Invention relates to field of pharmacology and medicine and deals with application of trecresan as medication which increases concentration of lactoferrin in blood.
Agent inducing hemopoietic stem cell differentiation into thrombocytes Agent inducing hemopoietic stem cell differentiation into thrombocytes / 2482870
Invention refers to medicine. What is declared is an agent inducing the hematopoietic stem cell differentiation into thrombocytes, representing a recombinant human cyclophilin A (rhCfA).
Hemostimulant and pharmaceutical composition and method for hemopoiesis stimulation Hemostimulant and pharmaceutical composition and method for hemopoiesis stimulation / 2482869
Invention refers to pharmaceutical composition and medicine, and represents a hypoglycemic, hypocholesteremic, hypolipidemic and (or) antioxidant combination of bis-(γ-L-glutamyl)-L-cysteinyl-glycine in the form of disodium salt and lipoic acid in the form of sodium salt, and coordination compounds formed by palladium, copper and γ-L-glutamyl-L-cysteinyl-glycine wherein the molar ratio of bis-(γ-L-glutamyl)-L-cysteinyl-glycine of disodium salt : palladium : copper is found within the range of 100-10000 : 1-10:1-10.
Method of treating viral hepatitis c Method of treating viral hepatitis c / 2496512
Group of inventions refers to medicine, namely to gastroenterology and may be used for treating hepatitis C. For this purpose, an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof is introduced into the patient. The above agent may be administered in a combination with pegylated interferon and ribavirin. The group of inventions also refers to a pharmaceutical composition for treating viral hepatitis C. This group of inventions enables disclosing a new drug preparation having a manifested antiviral effect and being effective in treating viral hepatitis C.
Method of treating visceras / 2495683
Invention relates to medicine, namely to methods of treating diseases of various aetiologies and injuries of various visceras. Electropunctural pre-examination aims at determining the patient's overall potential and the potential in a point on the body surface at a minimal distance from the viscera to be treated, or in its immediate projection tender zones. A stem cell growth area is stimulated by placing a bee within the sternum. Then, an irritation centre is created using vacuum- or hirudotherapy in a point on the body surface at a minimal distance from the above viscera or in its immediate projection tender zones. The irritation centre is created to be intensive and short-term at the level of the potential in the point below the overall potential, or to be weak and long-term at the level of the potential in a point above the overall potential.
Method for preventing and treating liver dystrophy in cattle / 2494759
Invention relates to therapy of internal non-infectious diseases, particularly to compositions for preventing and treating liver dystrophy in cattle. An agent for preventing and treating liver dystrophy in cattle contains an antihepatotoxic serum and an antispleenotoxic serum; the serums are pre-processed in acidic and enzymatic hydrolysis at pH 3.9-4.0 and pepsin concentration 49-51 mg per protein 100 g for 17.5-18.5 hours at temperature 37-38°C; then hydrolised serums are mixed with sterile saline, preserved phenol concentrated 0.4-0.5% at 1.0 ml thereof, the antihepatotoxic serum - 9.0-11.0 titre units and the antispleenotoxic serum - 9.0-11.0 titre units.
Synergetic preparation for treating cardiovascular diseases, diabetes mellitus and hepatobiliary diseases / 2493841
Invention refers to a synergetic preparation for treating cardiovascular insufficiency, types I and II diabetes mellitus, hepatobiliary diseases, containing a combination of a pharmaceutically acceptable salt of 2-ethyl-6-methyl-3-pyridin-3-ole and taurin in the amount of 2-75% and pharmaceutically acceptable carriers, excipients and additives with the mass ratio of the active ingredients of the combination making 9:1 to 1:9. The preparation may be presented in the form of a tablet, a capsule or a solution for injections. The invention also refers to a method of treating cardiovascular insufficiency, types I and II diabetes mellitus, hepatobiliary diseases wherein the therapeutically effective amount of the synergetic preparation is administered to the patient.
Treating fibrotic diseases Treating fibrotic diseases / 2491934
Present group of inventions refers to medicine, namely therapy, and concerns treating fibrotic diseases. That is ensured by administering 40-O-(2-hydroxy)ethylrapamycin or a pharmaceutical composition thereof in the effective amount.
Pharmaceutical composition containing 1,2-dithiol-thione derivative for preventing or treating diseases mediated by high lxr-alpha expression Pharmaceutical composition containing 1,2-dithiol-thione derivative for preventing or treating diseases mediated by high lxr-alpha expression / 2491065
Invention refers to pharmaceutics and medicine, and concerns a pharmaceutical composition for preventing and treating diseases mediated by high expression or high activity of liver X receptor (LXRa), high expression or high activity of a sterol regulatory element-binding protein-1c (SREBP-1).
Compositions of protectors against acute and chronic hepatic encephalopathies and method of treating acute and chronic hepatic encephalopathies Compositions of protectors against acute and chronic hepatic encephalopathies and method of treating acute and chronic hepatic encephalopathies / 2491062
Group of inventions refers to medicine and aims at treating and preventing hepatic encephalopathies. There are presented composite formulations containing various combinations of L-carnitine, acetyl-L-carnitine, succinate, L-glutamate, L-arginine, betaine and creatine phosphate, N-acetylcysteine, coenzyme Q10 and dihydroquercetin; S-adenosylmethionine; coenzyme Q10 and dihydroquercetin, dihydroquercetin and lipoamide.
Method for preparing conjugate of (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)acetaldehyde and 20-hydroxyecdysone and using it as antioxidant agent inhibiting lipid peroxidation process Method for preparing conjugate of (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)acetaldehyde and 20-hydroxyecdysone and using it as antioxidant agent inhibiting lipid peroxidation process / 2490267
Invention refers to organic chemistry and chemistry of natural products, more specifically to a method for preparing a new compound, a 20-hydroxyecdysone derivate conjugated with a short-chain vitamin E analogue, promising for medicine and pharmacology, namely to a method for preparing a 20-hydroxyecdysone conjugate by a reaction thereof with (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)acetaldehyde in ethyl acetate at room temperature in the absence of an acid catalyst (TsOH or phosphonomolybdic acid) for 24 h, debenzylation of the prepared intermediate conjugate in the ethanol solution in the presence of the catalyst Pd-C. The invention also refers to using such compound as an antioxidant agent inhibiting the lipid peroxidation process.
Method of dog's hepatosis therapy / 2490018
Invention refers to veterinary science, and may be used for dog's hepatosis therapy. The method for dog's hepatosis therapy involves using a hepatoprotector, a microelement and herbal tea; the hepatoprotector is presented by the preparation Ursosan containing 250 mg of ursodeoxycholic acid; the microelement is selenium, and herbal tea is aqueous-alcoholic extract of camomile blossom clusters and birch buds used sequentially orally: Ursosan 10 mg per 1 kg of animal's body weight, selenium 3 mg per 1 kg of animal's body weight, aqueous-alcoholic extract of camomile blossom clusters and birch buds 1 ml per 1 kg of animal's body weight for 30 days every 12 hours.
Method of conservative treatment of lithic stage of cholelithiasis / 2490017
Invention refers to medicine, particularly gastroenterology, and may be used for treating the lithic stage of cholelithiasis. For this purpose, ursodeoxycholic acid is administered for the night with underlying the mineral water Uvinskaya heated to 40-45°C.
Modified release pharmaceutical composition Modified release pharmaceutical composition / 2495666
Modified release pharmaceutical composition contains (1) (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetoacetanilide or a pharmaceutically acceptable salt thereof, (2) at least one additive which facilitates the water intrusion into the pharmaceutical composition and has a solubility such as a volume of water required to dissolve 1 g of the additive is equal to 10 ml or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100000 or more, or a viscosity of 12 mPa·s or more in 5% aqueous solution at 25°C.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, and represents an immunomodulator for treating chronic hepatitis, hepatic cancer, lymphatic sarcoma, chronic leukemia, and for improving the functions of liver and blood-forming organs, for enhancing the immunobiological body characteristics, prepared by mixing 1000 ml of an aqueous infusion of sandy everlasting blossom, pepper mint herb and chicory herb with 50 ml of bovine serum containing leukaemia oncovirus antibodies, 20 ml of wild rosemary infusion, 40 g of ascorbic acid, 2 g of sorbic acid, 0.2 g of folic acid until the ingredients are dissolved completely, with adding 60 g of liver powder, 30 g of lymphatic node powder, 30 g of young bovine spleen powder; the prepared solution is settled at room temperature for 24 hours, then kept at a boiling water bath for 30 minutes and cooled for 6-8 hours at room temperature; the settled solution is filtered, wherein the aqueous herbal solution is prepared by mixing equal proportions of the separately prepared aqueous infusions of 40 g of pepper mint herb in 1000 ml of water, 30 g of sandy everlasting blossom in 1000 ml of water and 30 g of chicory herb in 1000 ml of water, while the wild rosemary infusion is prepared by infusing 60 g of ground wild rosemary blossom in 1000 ml of 70% purified ethanol.

EFFECT: invention provides creating the high-efficacy agent and reducing the length of treatment.

 

The invention relates to the field of chemical and pharmaceutical industry, in particular to intended for the treatment of chronic hepatitis, liver cancer, limphosarcoma, chronic leukemia, and improve the functions of the liver and blood forming organs increase of immunobiological properties of the organism. Known «Vitogepat» derived from the liver of cattle, which is a complex of proteins and nukleoproteidov vitamins. The disadvantage of this drug is low therapeutic efficacy, inability to achieve long-term remission and full . The purpose of creation of the invention is to increase medical efficiency and reduction of terms of treatment of the above diseases. This objective is achieved by the immunomodulator additionally contains powder from the lymph nodes and spleen cattle serum of cattle containing antibodies to , Hemlock tincture, aqueous solutions of flowers bessmertnika sand, from grass peppermint, chicory, ascorbic acid, and folic acid in the trail. components:

Powder liver of cattle - 6,0,

Powder lymph nodes to 3.0,

Powder spleen - 3,0,

- Cattle serum containing antibodies to - ml to 5.0

- Hemlock tincture to 2.0 ml

- Flowers of immortelle sandy - 3,0,

- Grass peppermint - 4,0,

- Grass chicory - 3,0,

- Ascorbic acid - 4,0,

- Sorbic acid - 0,2,

- Folic acid, 0,02

- Distilled water up to 100.0 ml

Comparison of the proposed drug with other well-known in the field of medicine and pharmaceutical industry showed its compliance with the criteria of the invention.

Manufacturing of medicinal forms from raw materials of animal origin:

- Liver, lymph nodes(submandibular, , mediastinal) and spleen are selected in young cattle, at the age of 1-1,5 years, without clinical and laboratory manifestations of non-contagious, infectious and parasitic diseases immediately after the slaughter. Bodies are washed with running water and placed in the refrigerator at a temperature of +2+4 C, the 7 day cooling and conservation of biologically active substances. After this time authorities are cleared from the adipose tissue, finely crushed and put in an oven, each authority separately at a temperature of +60 C for 72 hours. Drying cupboard authorities turned over 24 hours since the beginning of drying. In the apparatus is threefold degreasing 96% ethyl alcohol. The vacuum drying Cabinet is removed extractant. Next, the resulting mass separately by the authority is passed through ball mill to powder-like state.

- Manufacturing of serum cattle containing antibodies to , leukemia virus inactivation and preservation of antibodies. At this stage you need to interact with experts of the state veterinary service in rural areas. During routine diagnostic studies cattle on leukemia, selected cows aged 4 to 6 years, positively reacting to leukemia by the reaction of the immune diffusion (RID). Next, the blood of these animals investigate hematological indicators are fine on the number of cells. Selected animals in which the number of white blood cells is 80 thousand and more (1 mm 3 ). This is the period when the disease passes from the blood stage of the tumor. From these animals is taken blood in the volume of 1 litre per head in glass flasks and separated serum. Then, the serum shimmers in 200 ml glass bottles of 100 ml and in them is filled in 100 ml of 70% of the pure ethyl alcohol. The mortar is mixed to obtain a homogeneous mass of white, after which the bottles are closed with rubber stoppers and rolled aluminium caps. Before adding to the product the contents of the vial thoroughly shaken.

Manufacturing of medicinal forms from raw materials of plant origin:

- Medicinal raw material is preliminary crushed with the size of particles passing through a sieve with apertures of 5 mm.

- Preparation infusions of herbs. Infusion of peppermint: in the heated will be 40, herbs, mint and filled with 1000 ml distilled water at room temperature and infused in water bath for 15 minutes with a boiling point with periodic . After that removed, extractor fan cooled at room temperature, same with occasional stirring at least 45 minutes, then filtered through a 4-layer gauze filter.

- Infusion of herbs chicory and flowers bessmertnika sand is prepared similarly, in the ratio of 30:1000.

- Preparation of Hemlock tincture. Tincture is prepared from freshly picked inflorescences of Hemlock in the first half of August. Placed in a flask 60 g of crushed flowers and filled with 1000 ml of 70% of the pure ethyl alcohol infused for 1 month. During this time, the contents periodically mixed. After this time tincture is filtered through a 6-layer gauze filter. The precipitate is discarded. Is stored in the dark place at room temperature.

Technology of preparation of the drug

In 1000 ml infusions flowers bessmertnika sand, grass peppermint and chicory in equal parts added 20 ml of tincture of Hemlock, 50 ml of serum antibodies of after a thorough shaking, 40 g, ascorbic acid, 2, sorbic acid and 0.2, folic acid. The resulting solution is stirred until complete dissolution of the ingredients. In placed 60 g of powder from the liver, 30 g of powder from the lymph nodes, 30 g of powder from the spleen cattle, and filled with 1000 ml of the solution prepared together with sludge. The solution is thoroughly mixed and left for 24 hours at room temperature for swelling, with occasional stirring. After this time is placed in a water bath for 30 minutes with a boiling point, with constant stirring. Then it's removed from the water bath and cooled 6-8 hours at room temperature. To defend the liquid is filtered through a funnel Buechner sediment is discarded. Finished product is packaged in glass bottles of 200 ml and sterilized at a temperature of +100 C for 30 minutes.

Testimony to the use of the drug are:

Chronic hepatitis, liver cancer, lymphoma, chronic leukemia, improvement of the liver and blood-forming organs, improvement of immunobiological properties of the organism. The preparation is applied inside adults and 5 ml of 1 times a day after meal for 20-30 days. In cancer of the liver, lymphosarcoma, chronic leukemia 5 ml, 2 times a day for 30-40 days. Children, depending on age, 1.0 ml to 3.0 ml of 1 time per day for 20-30 days. Repeated courses of treatment can be carried out not earlier than 3 months. Contraindications are acute liver failure, severe coronary insufficiency. The drug belongs to the list B and stored at a temperature of +5, +10oC C. Shelf life of 12 months, is produced in glass bottles with a capacity of 200 ml

The proposed immunomodulator «Hepato- co» is phyto-cytostatic drug, the integrated nature, broad-spectrum, is made exclusively of raw materials of animal and plant origin, which has no elements synthesis of chemical compounds. This medicine acts on the body on the principle of «similarity». When ingestion is rapidly absorbed from the gastrointestinal tract into the blood and has a pronounced anti-inflammatory effect on the liver parenchyma and lymph nodes, causing regeneration inflammatory sites. Components of the drug have antispasmodic and tonic action, reinforce cholagogue and bile secretion, reducing the level of bilirubin, blood cholesterol, prevent the stagnation of bile, improves metabolic function of the liver. Regulate carbohydrate and protein metabolism, thereby significantly improving the functional activity of the liver, increases the nitrogen in the urine. Under the influence of the drug improves the function of blood, that allows to develop full-fledged blood cells and restore the normal transport of oxygen to organs and tissues, improve metabolic processes in the body. Introduction in structure of immunomodulator serum antibodies to due to the fact that the causative agent of bovine leukemia and people is one of the same RNA-containing virus belonging to the family of retroviruses and kind of. This virus is identical affects the hematopoietic system in both people and animals, circulating blood and lymph nodes throughout the body. Cancer cells caused by this virus can in any organs and cause malignant neoplasms. Therefore, this serum passively body and allows to produce its own antibodies to , and ultimately the development of immunity. The drug is generally inhibits the growth and development of cancer cells, prevents metastasis, is a powerful nutrient stimulator and increases immunobiological properties of the organism.

The proposed immunomodulator possible and expedient to use in both inpatient and outpatientclinics during the treatment of diseases such as chronic hepatitis, liver cancer, limphosarcoma, chronic leukemia, and improve the functions of the liver and blood-forming organs, increase of immunobiological properties of the organism.

Sources of information:

- Directory of medicines under the editorship of M. Klyuyev, book house Locus reepol classic «Lada» Moscow 2006, p.154.

- Directory of infectious diseases of animals edited by J.F. ñ . Moscow, IN «» 1987, .152.

- Infectious and parasitic diseases human edited by B.A. Cherkassky. Moscow, publishing house «Medical newspaper», 1989, page 319.

Immunomodulator for the treatment of chronic hepatitis, liver cancer, limphosarcoma, chronic leukemia and improve the functions of the liver and blood-forming organs, increase of immunobiological properties of the organism, obtained by mixing 1000 ml of water infusion of flowers bessmertnika sand, grass peppermint grass chicory with 50 ml of serum cattle containing antibodies to leukemia, 20 ml of tincture of Hemlock, 40 grams of ascorbic, 2 g sorbic, 0.2 g of folic acid before full dissolution of all components, with the subsequent addition of 60 g powder liver, 30 g powder lymph nodes, 30 g powder spleen young cattle, with the further pursuit of the obtained solution at room temperature for 24 hours and then keeping on a boiling water bath during 30 min and cooling for 6-8 hours at a room temperature, and filtering solution, where water infusion of herbs prepare by mixing equal ratio separately received infusions of water 40 g herbs, mint in 1000 ml of water, 30 g flowers bessmertnika sand 1000 ml of the water and 30 g of grass chicory in 1000 ml of water, and Hemlock tincture receive macerating 60 g of crushed inflorescences of Hemlock in 1000 ml of 70% of the pure ethyl alcohol.


 

© 2013-2014 RussianPatents.com